chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 45 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 18Mar2021 11:45 (Lot number: EP6955) at the age of 45 years as dose 2, single for Covid-19 immunisation. Relevant medical history included: "Cardiomyopathy" (unspecified if ongoing). Concomitant medication(s) included: COREG. Vaccination history included: Bnt162b2, administration date: 26Feb2021, for Covid-19 immunization. The following information was reported: NAUSEA (non-serious) with onset 18Mar2021 13:15, outcome "recovered" (Mar2021), described as "felt sick to her stomach twice"; PAIN (non-serious) with onset 18Mar2021 13:15, outcome "recovered" (Mar2021), described as "achy"; FATIGUE (non-serious) with onset 18Mar2021 13:15, outcome "recovered" (Mar2021), described as "tired". Therapeutic measures were not taken as a result of nausea, pain, and fatigue. Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient also received unspecified vitamins and birth control and Entresto (as reported) within 2 weeks of vaccination. No follow-up attempts are possible. No further information is expected.
PT. INCORRECTLY GIVEN PFIZER AS HER 2ND COVID SHOT INSTEAD OF MODERNA, TO MATCH HER 1ST SHOT...NO ADVERSE REACTION.
Pt had HIB and VZV developed a large 4cm nodule with erythema (cellulitis appearance) on (L) thigh Reduced in size to 1 1/2 cm nodule by 3 w post vaccine. Had same rxn from HIB previously and pea-sized lump still present from 6 m dose-6 m later.
Received expired doses of the Moderna COVID vaccine; Vaccines placed in refrigerator was on 13 Jan 2022 but doses were administered to patient on 17 Feb 2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received expired doses of the Moderna COVID vaccine) and PRODUCT STORAGE ERROR (Vaccines placed in refrigerator was on 13 Jan 2022 but doses were administered to patient on 17 Feb 2022) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 068H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Feb-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2022, the patient experienced PRODUCT STORAGE ERROR (Vaccines placed in refrigerator was on 13 Jan 2022 but doses were administered to patient on 17 Feb 2022). On 17-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received expired doses of the Moderna COVID vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received expired doses of the Moderna COVID vaccine) and PRODUCT STORAGE ERROR (Vaccines placed in refrigerator was on 13 Jan 2022 but doses were administered to patient on 17 Feb 2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that the vaccines placed in refrigerator was on 13 Jan 2022, expiration date placed on vial was on 12 Feb 2022 and doses administered to patient on 17 Feb 2022. No treatment information was provided.
Mild redness at the site of the injection on left arm; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE ERYTHEMA (Mild redness at the site of the injection on left arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Mild redness at the site of the injection on left arm). At the time of the report, VACCINATION SITE ERYTHEMA (Mild redness at the site of the injection on left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.   Reporter did not allow further contact
Cough/sneezing/runny nose - head congestion (flu sx) occurring within one hour of administration - resident requesting report to be filed.
Patient described swelling in armpits/lymph nodes on side of vaccination a few days following vaccination. She also reported neck swelling, should pain. She reported no fever but body aches/chills for about 2 weeks. Patient had to go to urgent care to start steroid dose pack and muscle relaxer to help with pain/inflammation.
Pt recvd a series of 3 doses of Engerix-B vax, 3rd dose given 13FEB91; 03APR91 titer level determined that pt did not seroconvert; Booster dose was administered;
Developed rash over most of upper body down to upper thighs with intense itching and burning. Excessive skin shedding and hair loss. Diagnosed as PRP - Pityriasis Rubra Pilaris.
3/8/2021 onset rapid a fib, failed chemical cardio version requiring emergent DC cardioversion at hospital with no prior known history of arrhythmia.  Following discharge, patient discontinued Norvasc and initiated on beta blocker therapy and anticoagulation. Intolerant of beta blocker with two subsequent syncopal events with temporary loss of consciousness. Patient?s blood pressure has remained labile with confirmed orthostatic hypotension. AM hypertension. Patient underwent echocardiogram displaying a not previously noted mildly dilated aortic root, otherwise unremarkable. Successfully passed non-pharmacological stress test. Tilt table test positive with nitro induction- patient syncopal with blood pressures in 80/40?s and non-compensatory heart rate in the high 30-low 40?s. Cardiology suspects this is potentially an autonomic dysfunction. Patient with no prior syncopal events.  On 8/1, patient suffered traumatic fall with distal tibial spiral fracture, malleolar fracture, and proximal fibular spiral fracture. Tibia fixated with rod- malleolus fixated with screw. Fibula approximated intro-operatively. Patient intolerant of sitting on side of bed and standing upright. Upon standing, patient?s blood pressure 59/40 with first palpated pulse in 50?s. Patient requiring ICU step down monitoring as of day 7 with recommendation to report this sequence of events into the VAERS system.
Patient got vaccinated and was walking over to observation area. Before he sat down, he passed out, hitting his face on the ground.
been having some headaches off and on that she is not used to having; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (been having some headaches off and on that she is not used to having) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE and ROSUVASTATIN for an unknown indication.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (been having some headaches off and on that she is not used to having). At the time of the report, HEADACHE (been having some headaches off and on that she is not used to having) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information provided.
This case was reported by a consumer via interactive digital media and described the occurrence of adverse event in a patient who received DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis. On an unknown date, the patient received Tdap Vaccine at an unknown dose. On an unknown date, unknown after receiving Tdap Vaccine, the patient experienced adverse event (serious criteria life threatening). On an unknown date, the outcome of the adverse event was unknown. It was unknown if the reporter considered the adverse event to be related to Tdap Vaccine. Additional details were provided as follows: The age at vaccination was not reported. The patient cannot had this. The patient had life threatening reaction to Tdap.
brain fog; memory issues; visual problems; Floaters; Sensitivity to light; headaches; cognitive challenges; vaccine location=Left leg; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An 18-year-old male patient received BNT162b2 (BNT162B2), in Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 18 years intramuscular, in left leg for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: EP6955, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 12May2021, when the patient was 18-year-old, for COVID-19 immunization, reaction(s): "Inappropriate schedule of vaccine administered"; BNT162b2 (Dose Number: 1, Batch/Lot No: EP6955, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 22Mar2021, when the patient was 17-year-old, for COVID-19 immunization. The following information was reported: PRODUCT ADMINISTERED AT INAPPROPRIATE SITE (non-serious) with onset Dec2021, outcome "unknown", described as "vaccine location=Left leg"; VITREOUS FLOATERS (non-serious) with onset 10Jan2022, outcome "not recovered", described as "Floaters"; PHOTOPHOBIA (non-serious) with onset 10Jan2022, outcome "not recovered", described as "Sensitivity to light"; FEELING ABNORMAL (non-serious) with onset 10Jan2022, outcome "not recovered", described as "brain fog"; COGNITIVE DISORDER (non-serious) with onset 10Jan2022, outcome "not recovered", described as "cognitive challenges"; HEADACHE (non-serious) with onset 10Jan2022, outcome "not recovered", described as "headaches"; MEMORY IMPAIRMENT (non-serious) with onset 10Jan2022, outcome "not recovered", described as "memory issues"; OCULAR DISCOMFORT (non-serious) with onset 10Jan2022, outcome "not recovered", described as "visual problems". The events "brain fog", "memory issues", "visual problems", "floaters", "sensitivity to light", "headaches" and "cognitive challenges" required physician office visit and emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of feeling abnormal, memory impairment, ocular discomfort, vitreous floaters, photophobia, headache, cognitive disorder.  Additional information: Patient received treatment with Zithromax, Vitamin Supplements.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Delayed circular rash on left arm around the injection site.   Red, swollen, hot to touch.   Redness and swelling wraps around approx 70% of the arm.
Patient stated she is an RN, she asked for 2 Benadryl because she "felt funny". Patient stated she has had a "reaction" to the flu shot in the past. at 8:55, BP- 148/90, Pulse Ox - 97, HR - 76, respirations - 18. Patient refused to get a ride home or for us to call an ambulance. Patient left our clinic at 9:10am.
Blood clot in the Right arm, s/s started 48 hours after first shot in the series.
Based on follow-up information received on 09 March 2015, the case became valid. Initial unsolicited report received from a non-healthcare professional on 10 November 2014. This case is invalid as the individual patient identifiers were not reported. The case is linked to 2014SA155403. A number of 5 to 6 patients (age and gender not reported), whose medical history and concomitant medication was not reported, had received a dose of FLUZONE ID (batch number, expiry date of vaccine, number of dose, route and site of vaccination was not reported) on an unspecified date. On an unspecified date, patient experienced large knot at injection site. Illness at the time of vaccination was not reported. Corrective treatment and laboratory investigations were not reported. At the time of this report, the outcome of the event was reported as unknown. Documents held by sender: none. Follow-up report received from a non-healthcare professional on 09 March 2015. This is a cluster of 2 cases and is linked to case number 2014SA155403. (Same vaccine and same lot number). A 26-year-old female patient had received an intradermal dose of FLUZONE ID (batch number: UT4992AA) in right deltoid on 31 October 2014. On 01 November 2014, one day after vaccination, the patient had experienced large knot at injection site and redness, swelling, painful at injection site. The patient required emergency room visit. Laboratory investigations included allergy testing and bloodwork. Results showed the patient was not allergic to injection. On an unspecified date, the outcome of the events was recovered.
SOB, INCREASING ON EXERTION, MINIMALLY PRODUCTIVE COUGH, UNDOCUMENTED FEVER BEGAN ON 1/28/2022
51 yo M admitted with chest pain and shortness of breath, given influenzae vaccine at 1000 on 10/25/05.  approximately 12 hours later pt developed fever of 103.5 and cellulitis at site of injection.  Pneumococcal vaccine was administered at the same time - it is unclear if the two vaccines were gven at the same site and/or mixed together.  Pt was treated with intravenous cefazolin and vancomycin for cellulitis.  72 hours after onset, area is still hot, red and swollen although pt reports it feels better.  Temperature declining. 11/14/05 - Per review of d/c summary cellulitis confirmed. Orthopnea was noted.
symptoms fever, chills, and fatigue first occurred 4/9 shortly after receiving shot, and lasted until 4/13  on 4/10 vomiting and temporary blindness after exercise occurred. the blindness episode did not last longer than 2-3min, but was described as complete vision loss and occurred 1-2min after intercourse.   on 4/14 an incident of ?blacking out? occurred during prolonged intense exercise
Narrative:  Timing error, 2nd dose given too soon 14 days after 1st dose.
Acute abdominal pain from time awake (6:00am) till 10:00am on said day. Pain subsided immediately after second emesis episode in the ER. Lab tests were conducted. Results showed no issues with kidneys, liver or pancreas.
This case was reported by a consumer and described the occurrence of allergy to vaccine in a 11-year-old female patient who received FLUARIX QUADRIVALENT (batch number 27LY3, expiry date unknown). On 23rd September 2017, the patient received FLUARIX QUADRIVALENT. In September 2017, less than a week after receiving FLUARIX QUADRIVALENT, the patient experienced allergy to vaccine and allergic reaction. On an unknown date, the outcome of the allergy to vaccine and allergic reaction were unknown. It was unknown if the reporter considered the allergy to vaccine and allergic reaction to be related to FLUARIX QUADRIVALENT. Additional details were reported as follows: The patient had an allergic reaction to the vaccine as diagnosed by the medical professionals. In order to treat the patient, the allergist would perform necessary allergy testing. The allergist wanted to obtain another vial of the exact same vaccine, same manufacturer and same lot number to perform the allergy testing. The reporter needed a full list including both active and inactive ingredients. The reporter initially requested the facility about the vaccine who referred to GlaxoSmithKline as they did not had information about the ingredients. The reporter asked if there any quad pre-filled syringes of the same lot number because the allergist specified it must be he same lot number. The reporter had doctor's order for this, which they are willing to provide. The reporter also stated that, they understand the vial had to kept refrigerated.
First felt super cold especially feet then super hot and bottoms of feet were burning. Had low grade fever 99.9 took Tylenol now much better but very hungry in the middle of the night
This spontaneous report as received from another health professional refers to a patient of unknown age and gender. No medical history or concurrent conditions were reported. The patient was vaccinated with dose 1 of GARDASIL on 02-AUG-2012. On 09-OCT-2012, the patient was vaccinated with dose 2 of GARDASIL and the patient was vaccinated with the third dose on 08-JAN-2013. No dosage information or route of administration was reported. It was reported that the patient received the third dose of GARDASIL one day before the 22nd week. No adverse symptoms were reported. Additional information was not provided. Additional information has been requested.
I was very sleepy and slept hard (which I do not usually do) all afternoon. Later, I developed red raised spots on my inner arms. They have scabbed over and are fading. I think they are called ? Lichenoid drug eruption ? according to my daughter who is a pediatrician and my son in law who is an ER physician.
This spontaneous report as received from a register nurse refers to a 6 months infant, of unknown gender. Medical history and concomitant conditions were not reported. On 29-JAN-2014, the patient was vaccinated with dose 3 of ROTATEQ lot #J007283; expiration date: 27-SEP-2014 (dose, strength and route were not reported). Secondary and concomitant therapies were not reported. Nurse called and stated that improperly stored ROTATEQ was administered to patient. No adverse effects reported. The nurse reported that vaccine dose received by patient was a vaccine improperly stored as follows: On 13-JAN-2014, ROTATEQ was stored outside of recommended temperatures for 2 hours (2 pm - 4 pm) the temperature recorded was 50 degrees F. On 18-JAN-2014, ROTATEQ was stored outside of recommended temperatures for 2 hours (2 pm - 4 pm) the temperature recorded was 49.1 degrees F. On 10-FEB-2014, ROTATEQ was stored outside of recommended temperatures for 6 hours (12 pm - 6 pm) the temperature recorded was 51.8 degrees F. On 16-FEB-2014, ROTATEQ was stored outside of recommended temperatures for 5 hours (12 pm - 5 pm) the temperature recorded was 51.8 degrees F. On 22-FEB-2014, ROTATEQ was stored outside of recommended temperatures for 4 hours (2 pm - 6 pm) the temperature recorded was 52.7 degrees F. On 09-MAR-2014, ROTATEQ was stored outside of recommended temperatures for 2 hours (12 pm - 10 pm) the temperature recorded was 55.4 degrees F. On 15-MAR-2014, ROTATEQ was stored outside of recommended temperatures for 6 hours (8 am - 2 pm) the temperature recorded was 50 degrees F. On 16-MAR-2014, ROTATEQ was stored outside of recommended temperatures for 20 hours (2 am - 10 pm) the temperature recorded was 64.4 degrees F. On 17-MAR-2014, ROTATEQ the temperature reading on the morning was 64.8 degrees F. The total of hours stored outside of recommended temperatures was 55 hours. This is one of several reports from the same reporter. Additional information has been requested.
He experienced redness and 2  blotchy red circles on his left arm near the injection site. The blotchiness lasted for 2 days, and his doctor was consulted but no treatment was recommended. He has recovered fully with no lingering symptoms.
I felt that maybe they administered it too high, like the muscle area of my deltoid, and then around 10PM my shoulder started to hurt and then the next morning my pain level was 9/10 and it was unbearable.  I was very fatigued and could not use my arm to work since the pain in the arm. I took some Ibuprofen and took a nap and then after that it got a little better, it still hurt but at least I could I use my arm. The next day it was fine.
pt recv vax on Thursday evening-Friday arms tender;Sat AM area was red & hard size of golf ball;applied ice, used DPH during the afternoon;Sunday areas was inc to size of an egg, warm to touch, was tender into shoulder joint;painful to lift
Vaccination site warmth; Vaccination site erythema; Vaccination site pain; Vaccination site tenderness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Vaccination site warmth), VACCINATION SITE ERYTHEMA (Vaccination site erythema), VACCINATION SITE PAIN (Vaccination site pain) and VACCINATION SITE PAIN (Vaccination site tenderness) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Apr-2021, the patient experienced VACCINATION SITE WARMTH (Vaccination site warmth), VACCINATION SITE ERYTHEMA (Vaccination site erythema), VACCINATION SITE PAIN (Vaccination site pain) and VACCINATION SITE PAIN (Vaccination site tenderness). At the time of the report, VACCINATION SITE WARMTH (Vaccination site warmth), VACCINATION SITE ERYTHEMA (Vaccination site erythema), VACCINATION SITE PAIN (Vaccination site pain) and VACCINATION SITE PAIN (Vaccination site tenderness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication were provided. Patient took a steroid shot as treatment medication.
arrives to the emergency department in acute respiratory distress. endorses being sick with trouble breathing and chest pain 3 days after the vaccine booset
Patient has a large golf ball sized red inflammation where the vaccine was administered, there is a small hard nodule about the size of a quarter.
L leg muscle (suspect sartorius muscle) intermittent spasm starting the day after vaccination and persisting intermittently for 2+ days.  Improving with Motrin at time of this report, but not resolved.
Migraine headache, fatigue, started feeling depressed and overall not feeling well initially and symptoms continued on and off through summer.  In Fall, severe migraine headaches, Difficulty concentrating, major depression, anxiety, feeling different, constant cough, constant congestion.
Patients were administered vaccine that were in the refrigerator beyond 30 days; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patients were administered vaccine that were in the refrigerator beyond 30 days) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patients were administered vaccine that were in the refrigerator beyond 30 days). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patients were administered vaccine that were in the refrigerator beyond 30 days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Treatment medications were not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Initial Additional-1
Numbness in left hand. Left arm heavy and sore.Fever. Chills. Cough. Heart palpable. Shortness of breath. Stomach cramps. Nausea. Diarrhea. Pain behind eyes. Burning itchy skin. Uterine bleeding.
On day 9 after the shot the area around the injection site became very itchy and warm and shortly after a rash started appearing. I used topical hydrocortisone cream and Caladryl.    The rash ended up being about 2" x  3" in size. It felt slightly sore but not much.   I took pictures if you want them. After  few days I took a Benadryl product as my whole body started feeling slightly itchy off and on but I think thats just from being nervous about arm rash.